Any disease of the lung induced by a fungus.

Mycosis of the lung may be caused by conditions where fungal infections invade body systems. This invasion may occur by inhalation of mold, spores, or dust that has been contaminated with fungal organisms from bat or bird droppings, such as in aspergillosis (see Diagnostic Code: 6838 Aspergillosis), or any of the mycotic lung diseases (see Diagnostic Code: 6834 Histoplasmosis of lung, Diagnostic Code: 6835 Coccidioidomycosis, Diagnostic Code: 6836 Blastomycosis, Diagnostic Code: 6837 Cryptococcosis, Diagnostic Code: 6838 Asperigillosis, or Diagnostic Code: 6839 Mucormycosis). Mycosis may also be caused by invasion via damaged skin, such as in Cutaneous T-cell lymphoma (see Diagnostic Code: 7817 Erythroderma), when the tumor stage of the disease progresses. Corticosteroids, antineoplastics, immunosuppressives, or multiple antibiotics used in the treatment of seriously ill individuals or those with compromised immunity can also be causes of pulmonary mycosis. Occupational or environmental exposures, and the specific fungal organism may be relative to the individuals' geographic location.

Signs and symptoms may resemble bacterial pneumonia (see Analogous code: 6899-6845 Pneumonia), tuberculosis (see Diagnostic Code: 6730 Tuberculosis, pulmonary, chronic), or flu-like symptoms. Major symptoms may include: cough; weakness; chest pain; fever; shaking chills; dyspnea; hypoxia; production of purulent greenish, brownish, or blood-tinged sputum; rales; rhonchi; and loss of appetite. Extrapulmonary lesions may involve one or more tissue sites, e.g., bones, joints, skin, brain, abdominal organs, meninges, lymph nodes, or skin. Ulcerations of the gastrointestinal tract may be evident. Granulomatous lesions may be visualized with radiologic studies.

Cultures of sputum and other body fluids best identify the infectious organism. In addition, radiological studies of the chest, blood studies, and skin tests may also be used for organism identification.

Antifungal medications, and monitoring of fungal serology titers and renal function studies may be implemented. Surgical intervention may be needed to control bleeding, drain abscesses or pleural fluids, or to remove nodules.

There is potential for medications to adversely affect the gastrointestinal (GI) tract, liver, bone marrow, and kidneys. Severe infections can lead to death.

None.